Co-Diagnostics, Inc. Launches CE-Marked Multiplex Test at CARPHA 2019
June 25 2019 - 6:30AM
Business Wire
Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular
diagnostics company with a unique, patented platform for the
development of molecular diagnostic tests, today announced the
launch of their Logix Smart™ ZDC multiplex test at the 64th Annual
2019 Caribbean Public Health Agency (CARPHA) Health Research
Conference.
The ZDC multiplex test was designed to detect the presence of
Zika, dengue, and chikungunya within a single polymerase chain
reaction (PCR) test. Its performance confirms the heightened
specificity provided by the Company’s CoPrimer™ platform in
multiplex PCR applications. Co-Diagnostics received CE mark
approval for their ZDC multiplex test after validating its
performance, which allows the diagnostic to be sold throughout the
European Community, Latin America, the Caribbean Basin, as well as
any other jurisdiction that accepts a CE mark as valid regulatory
approval.
Co-Diagnostics, Inc. CEO Dwight Egan remarked, “Our CE-marked
ZDC multiplex test for Zika, dengue, and chikungunya was designed
specifically to meet the demands of markets where these diseases
are present, including countries in Europe, Central and South
America and the Caribbean region. The development-to-regulatory
approval turnaround time of about 6 months underscores our ability
to quickly and efficiently design, develop, and validate
high-quality molecular diagnostics.
“In the time since the last CARPHA conference, we have CE-marked
three infectious disease diagnostics, including the ZDC multiplex
test, received US patent protection for our CoPrimer technology,
completed several significant proof-of-concept studies showing our
technology’s applications in NGS, launched our mosquito vector
control program domestically, and signed a technology license
agreement with an international leader in the life sciences sector
operating in 19 countries worldwide. Attending the conference this
year has positioned us to monetize these advancements, and to
strengthen our relationships with researchers and health
professionals from across North America, Europe, Latin America, and
the Caribbean Region.”
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular
diagnostics company that develops, manufactures and markets a new,
state-of-the-art diagnostics technology. The Company’s technology
is utilized for tests that are designed using the detection and/or
analysis of nucleic acid molecules (DNA or RNA). The Company also
uses its proprietary technology to design specific tests to locate
genetic markers for use in industries other than infectious disease
and license the use of those tests to specific customers.
Forward-Looking Statements:
This press release contains forward-looking statements.
Forward-looking statements can be identified by words such as
"believes," "expects," "estimates," "intends," "may," "plans,"
"will" and similar expressions, or the negative of these words.
Such forward-looking statements are based on facts and conditions
as they exist at the time such statements are made and predictions
as to future facts and conditions. Forward-looking statements in
this release include statements regarding the (i) use of funding
proceeds, (ii) expansion of product distribution, (iii)
acceleration of initiatives in liquid biopsy and SNP detection,
(iv) use of the Company’s liquid biopsy tests by laboratories, (v)
capital resources and runway needed to advance the Company’s
products and markets, (vi) increased sales in the near-term, (vii)
flexibility in managing the Company’s balance sheet, (viii)
anticipation of business expansion, and (ix) benefits in research
and worldwide accessibility of the CoPrimer technology and its
cost-saving and scientific advantages. Forward-looking statements
are subject to inherent uncertainties, risks and changes in
circumstances. Actual results may differ materially from those
contemplated or anticipated by such forward-looking statements.
Readers of this press release are cautioned not to place undue
reliance on any forward-looking statements. The Company does not
undertake any obligation to update any forward-looking statement
relating to matters discussed in this press release, except as may
be required by applicable securities laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190625005364/en/
Andrew Benson Co-Diagnostics Investor Relations 801-438-1036
investors@codiagnostics.com
Co Diagnostics (NASDAQ:CODX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Co Diagnostics (NASDAQ:CODX)
Historical Stock Chart
From Sep 2023 to Sep 2024